HOLDING LTD ROCHE stock holdings and net worth by SEC Form 4 filings Mar, 2024 (2024)

FAQs

Is Roche Holding a good investment? ›

The highest analyst price target is $379.10 ,the lowest forecast is $260.28. The average price target represents -4.29% Decrease from the current price of $320.19. Roche Holding AG's analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

Roche Holding AG has a market cap or net worth of $264.72 billion as of August 2, 2024. Its market cap has increased by 736.22% in one year.

Largest shareholders include VGTSX - Vanguard Total International Stock Index Fund Investor Shares, VTMGX - Vanguard Developed Markets Index Fund Admiral Shares, IEFA - iShares Core MSCI EAFE ETF, DODFX - Dodge & Cox International Stock Fund, EFA - iShares MSCI EAFE ETF, FSPSX - Fidelity International Index Fund, MGRAX ...

RHHBY pays a dividend of $0.88 per share. RHHBY's annual dividend yield is 2.08%. When is Roche Holding ex-dividend date? Roche Holding's previous ex-dividend date was on Mar 14, 2024.

Roche reports 5% (CER) sales growth in the second quarter of 2024. Commenting on the results, CEO Thomas Schinecker said: “Our strong sales growth in the first half of 2024 reflects the high demand for our innovative medicines and diagnostics.”

Family. The Hoffmann-La Roche family is Switzerland's richest and one of the most secretive families. Many members of the family don't carry the last name Hoffmann anymore.

Cash on Hand as of December 2023 : $12.50 B.

The company discovers, develops, and sells pharmaceutical products globally. Its drugs are used for the treatment of various types of diseases, including cancer, heart-related, and infectious, among others.

Novartis started building a stake in Roche back in May 2001 as a long-term financial investment. The company reached its current stake by 2003 after investing a total of about $5 billion. In addition to the obvious share price gain, the holding also yielded over $6 billion of dividends over the years.

Who did Roche merge with? ›

25, 2019 (GLOBE NEWSWIRE) — Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per ...

Roche is one of the largest global pharmaceutical companies and is based in Basel, Switzerland. In 2023, the Roche Group had nearly 104,000 employees worldwide. Roche is the world's leading pharmaceutical company in the area of oncology.

There is typically 1 dividend per year (excluding specials), and the dividend cover is approximately 1.8.

Brookfield Infrastructure Corporation

The quarterly dividend payable on the Brookfield Infrastructure Corporation's Class A shares are declared in U.S. dollars. Registered shareholders who are U.S. residents receive their dividends in U.S. dollars, unless they request the Canadian dollar equivalent.

Compared to the current market price of 281.1 CHF, Roche Holding AG is Undervalued by 22%. What is intrinsic value? Roche Holding AG's market capitalization is 224.1B CHF.

According to the 7 analysts' twelve-month price targets for Roche, the average price target is $40.00. The highest price target for RHHBY is $40.00, while the lowest price target for RHHBY is $40.00. The average price target represents a forecasted downside of -1.74% from the current price of $40.71.

RH stock prediction for 1 year from now: $ 404.43 (46.74%) RH stock forecast for 2025: $ 362.66 (31.58%) RH stock prediction for 2030: $ 1,430.56 (419.04%)

Also, with its next 12-month price-to-earnings multiple of 12.2x significantly below long-term averages, and a dividend yield above 6%, Pfizer stock could fit well into most value investors' portfolios.